Form 4 for INSM INSMED Inc
Accepted 2026-08-07 16:39:09 ET · period of report 2026-08-06 · accession 0001796960-26-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-07 16:39 | 2026-08-06 | INSM | Flammer Martina M.D. | Chief Medical Off | M - OptEx | $21.20 | +27.2K | 87.7K | +45% | +$576.1K |
| DMT | 2026-08-07 16:39 | 2026-08-06 | INSM | Flammer Martina M.D. | Chief Medical Off | S - Sale+OE | $128.61 | -27.2K | 60.5K | -31% | -$3.49M |
| DMT | 2026-08-07 16:39 | 2026-08-06 | INSM | Flammer Martina M.D. | Chief Medical Off | M - OptEx | $0.00 | -27.2K | 35.6K | -43% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-06 | M | A | 18,278 | $18.95 | 78,764 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 2 | Common | Common Stock | 2026-08-06 | M | A | 8,895 | $25.83 | 87,659 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 3 | Common | Common Stock | 2026-08-06 | S | D | 8,895 | $127.00 | 78,764 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 4 | Common | Common Stock | 2026-08-06 | S | D | 18,278 | $129.40 | 60,486 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F2) This is the weighted average sales price representing 18,278 shares sold at prices ranging from $129.40 to $129.41 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 5 | Derivative | Stock Option (right to buy) | 2026-08-06 | M | D | 18,278 | $0.00 | 36,555 | D | $18.95 · — to 2033-05-11 | 18,278 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F3) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 6 | Derivative | Stock Option (right to buy) | 2026-08-06 | M | D | 8,895 | $0.00 | 35,580 | D | $25.83 · — to 2034-05-13 | 8,895 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F4) The options become exercisable based on the following vesting schedule: 25% vest on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the Initial Vesting Date. |